Chrysalis BioTherapeutics, Inc. is a privately held biopharmaceutical development company working to save lives and improve life’s quality. The company is developing Chrysalin® brand thrombin peptide drugs to repair and regenerate tissues damaged by injury, disease, and radiation exposure. These drug products, derived from the wound healing molecule thrombin, use the body’s natural regenerative signals to activate and protect endogenous endothelial progenitor cells and stem cells located within tissues. These novel peptide drugs provide a natural alternative to most current drug and cellular therapies.
The company is focused on developing drug products to mitigate effects caused by two types of radiation exposure.
Nuclear Radiation: There is increasing risk of a nuclear accident or intentional detonation somewhere in the world with no medical solution to save lives and prevent long-term suffering. Injection of the company’s Chrysalin® brand thrombin peptide, TP508, 24 hours after nuclear exposure increases survival and accelerates wound healing in preclinical studies.
Radiation Therapy: Radiation therapy damages normal tissues causing long-term or permanent damage and limiting how much radiation can be used by oncologists to eradicate tumors. Treatment with the company’s Chrysalin® brand thrombin peptide, TP508, protects normal tissues from damaging effects of radiation therapy without affecting radiation killing of tumor cells.
The company is evaluating two additional areas of major unmet clinical needs for future development or partnering.
Cardiovascular Disease: Cardiovascular disease is the single largest killer of Americans, claiming the lives of over one million annually (American Heart Association). Preclinical studies have shown that TP508 reduces restenosis, protects heart muscle from effects of acute myocardial infarction, and helps to restore vascular perfusion and function to the left ventricle of hearts with chronic myocardial ischemia.
Tissue Repair and Regenerative Medicine: In spite of medical advances, there are no successful treatments for many types of injury and diseases especially in aging populations. Use of stem cell therapies are being used to address these clincal problems. Clinical trials and pre-clinical studies have shown potential efficacy of TP508 in treating diabetic foot ulcers, distal radius fractures, and neural regeneration. These effects are mediated by restoring function to vascular endothelial cells and by activating endogenous progenitor cells located within tissues. Thus, TP508 provides a natural alternative to stem cell therapy.